Sanofi ($SNY) is again trimming its oncology pipeline, walking away from an armed-antibody cancer treatment licensed from ImmunoGen ($IMGN) as it reshapes its approach to the field.
ImmunoGen disclosed that Sanofi has abandoned SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. The treatment combines an antibody engineered to target CD19--a protein expressed by tumors--with the cancer-killing agent maytansinoid, resulting in a targeted therapy.
http://www.fiercebiotech.com/story/sanofi-dumps-immunogen-cancer-drug-it-scales-back-oncology/2015-04-24?utm_medium=rss&utm_source=feedly&utm_campaign=rss
ImmunoGen disclosed that Sanofi has abandoned SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. The treatment combines an antibody engineered to target CD19--a protein expressed by tumors--with the cancer-killing agent maytansinoid, resulting in a targeted therapy.
http://www.fiercebiotech.com/story/sanofi-dumps-immunogen-cancer-drug-it-scales-back-oncology/2015-04-24?utm_medium=rss&utm_source=feedly&utm_campaign=rss
No comments:
Post a Comment